

## AVITA Medical Investor Conference Call Details

*Company to host conference call at 2:00 p.m. AEST Wednesday, 20 June 2018  
to discuss recent operational results and upcoming milestones*

---

**Valencia, Calif., USA, and Melbourne, Australia, 19 June 2018** — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications, today announced the Company will hold an investor conference call at 2:00 p.m. AEST on Wednesday, 20 June 2018, hosted by Dr. Michael Perry, Chief Executive Officer, and Dale Sander, Chief Financial Officer, to discuss recent operational results and upcoming milestones.

### Investor Conference Call details

Dial-in numbers for the investor conference call are as follows:

Australian Toll Free: 1 800 685 494

International callers: +61 3 8687 0650

A corporate slide presentation which will be referenced during the call will be posted to the ASX website (<https://www.asx.com.au>) and to the Company's website (<http://avitamedical.com>).

A recording of the call will be available on the Investors section of the Company's website for 60 days after the call.

### ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. Our medical devices work by preparing a REGENERATIVE EPITHELIAL SUSPENSION™, an autologous suspension comprised of the patient's own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This autologous suspension is then sprayed onto the areas of the patient to be treated.

In the United States, the RECELL Device is an investigational device limited by federal law to investigational use. In September 2017, AVITA Medical submitted to the U.S. Food and Drug Administration (FDA) a PreMarket Approval (PMA) application for RECELL for the treatment of burn injuries.

In all countries outside of Europe, our portfolio is marketed under the RECELL Device brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. RECELL Device is TGA-registered in Australia, and CFDA-cleared in China.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. RECELL Device is designed for the treatment of burns and plastic reconstructive procedures; REGENERCELL™ Autologous Cell Harvesting Device has been formulated for chronic wounds including leg and foot ulcers; and RENOVACELL™ Autologous Cell Harvesting Device is tailored for aesthetic applications including the restoration of pigmentation.

To learn more, visit [www.avitamedical.com](http://www.avitamedical.com).

#### **CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

*This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.*

#### **FOR FURTHER INFORMATION:**

<p><b>OUS Media</b> <b>Monsoon Communications</b> Sarah Kemter Phone: +61 (0)3 9620 3333 Mobile: +61 (0)407 162 530 <a href="mailto:sarahk@monsoon.com.au">sarahk@monsoon.com.au</a></p> <p><b>US Media</b> <b>Syneos Health Public Relations</b> David Polk Phone: +1 (310) 309 1029 Mobile +1 (805) 428 5775 <a href="mailto:david.polk@syneoshealth.com">david.polk@syneoshealth.com</a></p>	<p><b>Investors:</b> <b>Westwicke Partners</b> Caroline Corner Phone +1 (415) 202-5678 <a href="mailto:caroline.corner@westwicke.com">caroline.corner@westwicke.com</a></p> <p><b>AVITA Medical Ltd</b> Dale A. Sander Chief Financial Officer Phone +1 (858) 663-6993 <a href="mailto:dsander@avitamedical.com">dsander@avitamedical.com</a></p>
---	---